This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Critical components and policy initiatives include clinicians emphasizing the prevention of tobacco product initiation and supporting cessation with established pharmacological and behavioral tobacco dependence treatment therapies as primary goals for achieving an end to commercial tobacco and nicotine addiction.
AimsHistorically, atherosclerotic cardiovasculardisease (ASCVD) risk profile mitigation has had a predominant focus on low density lipoprotein cholesterol (LDL-C). Results from pharmacologically lowering triglyceride are conflicting.
Metabolic syndrome, today affecting more than 20% of the US population, is a group of 5 conditions that often coexist and that strongly predispose to cardiovasculardisease. How these conditions are linked mechanistically remains unclear, especially two of these: obesity and elevated blood pressure.
Atherosclerotic cardiovasculardisease is a major health concern worldwide and requires effective preventive measures. Circulation, Volume 151, Issue 6 , Page 400-415, February 11, 2025.
Optional Pre-conference Workshop to be held Friday afternoon includes a number of topics: Pharmacology 101 Pharmacology 101 – Workshop: Alana Ferrari, PharmD, BCOP How Do I Grow My Career in Cardio-Oncology? Course Vice Chair is Richard Cheng, MD, MSc, FACC , University of Washington. Friday, February 9 Registration (1:00 - 6:00 p.m.)
Faculty member Affiliation Professor Amitava Banerjee Professor of Clinical Data Science, Institute of Health Informatics, University College London; Consultant Cardiologist, University College London Hospitals and Barts Health NHS Trust Professor Sir Mark Caulfield Professor of Clinical Pharmacology, Queen Mary Un.
Introduction:Previous studies have suggested that increased body fat is associated with elevated cardiovasculardisease (CVD) risk. We have previously shown that apart from common vascular risk factor modification, adipose tissue-specific factors, such as adiponectin, may mediate the relationship between body fat and vascular risk.
The first procedures, performed by leading physicians Saibal Kar , MD, FACC, FSCAI, (Program Director, CardiovascularDisease Fellowship, Los Robles Health System , California, HCA Healthcare National Physician Director, Interventional Cardiology) and Devi Nair , MD, FACC, FHRS, (Director, Cardiac Electrophysiology Division, St.
Traditional Chinese herbal medicine (CHM) has been extensively used in cardiovasculardisease in modern clinical practice, alone or in combination with conventional treatment. CHM, with or without conventional treatment, showed a consistent beneficial effect in various cardiovasculardiseases.
The frequent concurrence of elevated blood pressure (BP) and type 2 diabetes markedly elevates the risk of cardiovasculardisease and mortality. The review introduces a mediation model, delineating the intricate interplay between hypertension and diabetes and their joint contribution to cardiovascular and renal pathologies.
There are numerous effective medications for modifying CAD but new pharmacologic therapies require increasingly large and expensive cardiovascular outcome trials to assess their potential impact on MACE and to obtain regulatory approval. For many disease areas, nearly a half of drugs are approved by the U.S.
Myocardial infarction (MI) and pulmonary artery hypertension (PAH) are two prevalent cardiovasculardiseases. Pterostilbene (PTE), an antioxidant compound, has been studied as a possible therapy for cardiovasculardiseases. In both conditions, oxidative stress is associated with a worse prognosis.
Cardiovascular Update for the Clinician: A Symposium by Valentin Fuster” will offer the latest advances in the treatment of cardiovasculardisease and ways to integrate them into daily practice. 24 Education Sessions Symposiums at ACC The “Symposiums at ACC.24”
Abstract: The renin angiotensin aldosterone system (RAAS) is a paramount target for the pharmacological treatment of cardiovasculardiseases. Such a comprehensive description may lead to a better understanding of the effects of pharmacological interventions in the RAAS. s.ramusovic@uni-duesseldorf.de
He discussed therapeutic options not only for treating atherosclerosis but also for preventing cardiovasculardisease. Aronne, MD , discussed advances in obesity pharmacology, while Virend K. Dr. Libby made a poignant observation, emphasizing that his LDL goal for patients is “ALARA: As Low As Reasonably Achieved.”
Aortic diseases such as atherosclerosis, aortic aneurysms, and aortic stiffening are significant complications that can have significant impact on end-stage cardiovasculardisease.
Risk factors for thrombotic stroke overlap strongly with those for other atherosclerotic cardiovasculardiseases (ASCVDs). Antiplatelet therapy (APT) should be considered in patients with established ASCVD to reduce risk of cardiovascular events, including stroke. Inflammation is another emerging target for stroke prevention.
24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24
BACKGROUND:S-Nitrosylation (SNO), a prototypic redox-based posttranslational modification, is involved in cardiovasculardisease. Aortic aneurysm and dissection are high-risk cardiovasculardiseases without an effective cure. Circulation, Ahead of Print.
BackgroundCardiac hypertrophy (CH) is a well‐established risk factor for many cardiovasculardiseases and a primary cause of mortality and morbidity among older adults. Currently, no pharmacological interventions have been specifically tailored to treat CH. Journal of the American Heart Association, Ahead of Print.
Using this data; the AI can further predict the patient’s cardiovasculardisease risk using optic disks and blood vessels. Alun Hughes, professor of Cardiovascular Physiology and Pharmacology at London’s UCL, said Google’s approach sounded credible because of the “long history of looking at the retina to predict cardiovascular risk.”
The supposition that beta blockade in the presence of cocaine intoxication would lead to unopposed alpha constriction is not based in accurate pharmacology, and the study that showed this effect with human intracoronary administration was done, as mentioned in the article, with propranolol, a nonselective beta blocker.
As a result, they serve as key targets for therapeutic interventions in cardiovasculardiseases. As a result, they serve as key targets for therapeutic interventions in cardiovasculardiseases. The objective of this article is to focus on the role that TRPC channels play in the cardiovascular system.
weight loss at 36 weeks for adults with obesity Pharmacology Consult: GLP-1 receptor agonists for weight loss management Combined GLP-1/amylin analog bests monotherapy for HbA1c drop, weight loss in diabetes ‘Watershed moment’: Obesity care in the spotlight as more drugs become available
Pharmacological Interventions : Use of antihypertensive medications, lipid-lowering agents, and antidiabetic drugs. Key Areas for Evidence Based Cardiometabolic Care Essential areas for evidence-based strategies in cardiometabolic care include: Lifestyle Interventions : Effective management of diet, physical activity, and weight.
Abstract: Cardiovasculardisease continues to be the leading cause of mortality globally. Modifiable risk factors, such as hypertension and dyslipidemia can be managed through lifestyle and pharmacotherapy treatments to reduce the risk of primary and secondary major cardiovascular events in patients with elevated risk.
Abstract: Studies have examined the therapeutic effect of levosimendan on cardiovasculardiseases such as heart failure, perioperative cardiac surgery, and septic shock, but the specific mechanism in mice remains largely unknown.
Hypertension is a major risk factor for cardiovasculardisease (CVD), and a major contributor to global morbidity and mortality. Hypertension is a major risk factor for cardiovasculardisease (CVD), and a major contributor to global morbidity and mortality.
Trimethylamine N-oxide (TMAO) is a gut microbial metabolite that has been associated with the increased risk of cardiovasculardiseases. Trimethylamine N-oxide (TMAO) is a gut microbial metabolite that has been associated with the increased risk of cardiovasculardiseases.
HECT-type E3 ubiquitin ligases (HECT E3s) participate in the progression of cardiovasculardiseases. HECT-type E3 ubiquitin ligases (HECT E3s) participate in the progression of cardiovasculardiseases.
Cardiovasculardisease (CVD) is the leading cause of morbidity and mortality globally. CVD and kidney disease are closely related, with kidney injury increasing CVD mortality. CVD and kidney disease are closely related, with kidney injury increasing CVD mortality.
Furthermore, the offspring of patients with type 2 diabetes and metabolic disorder syndrome may have a higher risk of diabetes and cardiovasculardisease, which indicates that the environmental impact on diabetes prevalence can be transmitted across generations.
Abstract: Type 2 Diabetes Mellitus (T2DM) increases the risk of cardiovasculardiseases. Therefore, elucidation of the cardiovascular effects of antidiabetics is crucial. Type 2 Diabetes Mellitus (T2DM) increases the risk of cardiovasculardiseases.
Air pollution is associated with excess thrombotic and cardiovascular events. However, clinical outcomes trials evaluating interventions to mitigate such adverse events in patients with atherosclerotic cardiovasculardiseases (ASCVD) are lacking. Air pollution is associated with excess thrombotic and cardiovascular events.
Abstract: Dapagliflozin (DAPA) is a novel oral hypoglycemic agent, and there is increasing evidence that DAPA has a protective effect against cardiovasculardisease. Dapagliflozin (DAPA) is a novel oral hypoglycemic agent, and there is increasing evidence that DAPA has a protective effect against cardiovasculardisease.
Coronary reactive hyperemia (CRH) is impaired in cardiovasculardiseases, and angiotensin-II (Ang-II) exacerbates it. Coronary reactive hyperemia (CRH) is impaired in cardiovasculardiseases, and angiotensin-II (Ang-II) exacerbates it. sEH-overexpression resulted in CRH-reduction in Tie2-sEH Tr versus WT.
LncRNA Metastasis-related lung adenocarcinoma transcript 1 (MALAT1) has been determined to play an important role in the modulation of oxidative stress and the development of cardiovasculardiseases. Nevertheless, the function and underlying mechanism of MALAT1 in restenosis induced by hypertensive angioplasty remain unclear.
Can Chen, Department of Cardiovasculardisease, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China, Telephone: +86-759-2369368, Fax: +86-759-2231754; E-mail: chencan-21@163.com The combination of Irbesartan and Emodin is better than single drug application. Correspondence to: Prof.
Atherosclerotic cardiovasculardisease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
Background We aimed to investigate the effectiveness of fixed-dose combination therapy (polypill) for primary and secondary prevention of major cardiovasculardiseases in a typical rural setting. This tablet comprised two antihypertensive agents, a statin and aspirin. Trial registration number NCT03459560.
Among the leading causes of natural death are cardiovasculardiseases, cancer, and respiratory diseases. Inconclusive clinical outcomes of vitamin D supplements in cardiovasculardiseases demonstrate the need to identify cause-effect relationships without bias.
Despite the existence of well-established risk factors and effective pharmacological treatments for major cardiovasculardisease (CVD), these conditions remain among the leading causes of premature death and disability, exerting a substantial burden on health systems worldwide.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
73 
Let's personalize your content